AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.

11/12/2026, 3:40 AM • GlobeNewswire

GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.

11/11/2026, 1:00 PM • GlobeNewswire

Nucleic Acid Labeling - Global Strategic Business Report 2026: Secure Share of a $2.8 Billion Market by 2032 as Thermo Fisher Scientific, Roche, Merck, and Agilent Accelerate Genomics

The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.

11/10/2026, 10:00 AM • GlobeNewswire

Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026

Roche announced new clinical data across its Alzheimer's disease portfolio at CTAD 2026, including Phase Ib/IIa data for trontinemab showing rapid amyloid removal, Phase III PrevenTRON study initiation for preclinical AD, and Phase II TARBELA-AD trial for NLRP3 inhibitor RG6434 targeting neuroinflammation. The company also highlighted its blood-based diagnostic tests Elecsys pTau217 and pTau181 for earlier and more accurate Alzheimer's diagnosis.

11/10/2026, 1:00 AM • GlobeNewswire

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.

11/09/2026, 5:00 AM • The Motley Fool

Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence

India's continuous glucose monitoring market is projected to grow at a CAGR of 11.90% from 2027-2032, reaching USD 452.9 million by 2032. The market expansion is driven by growing adoption of sensor-based monitoring, digital healthcare integration, and expanding diabetes management programs. However, high device costs and limited reimbursement coverage remain barriers to wider adoption.

11/03/2026, 2:30 AM • GlobeNewswire

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight

The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.

11/02/2026, 1:00 PM • GlobeNewswire

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity

Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.

10/28/2026, 11:00 AM • GlobeNewswire

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

Roche announced CE Mark approval for its cobas smart e immunoanalyser, a compact benchtop diagnostic platform designed to bring central-laboratory precision to smaller healthcare settings. The system features over 100 planned assays, reaction times of 18 minutes or less for 90% of tests, and requires minimal daily maintenance, addressing workforce shortages while enabling decentralized testing in resource-constrained environments.

10/27/2026, 2:00 AM • GlobeNewswire

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Roche announced pivotal phase III Krascendo 1 trial results showing its investigational drug divarasib significantly outperformed first-generation KRAS G12C inhibitors (sotorasib and adagrasib) in previously treated KRAS G12C-mutated non-small cell lung cancer. Divarasib achieved a median overall survival of approximately 18 months versus 12 months for competitors, reducing death risk by 44% and disease progression risk by 42%, with a manageable safety profile.

10/25/2026, 11:30 AM • GlobeNewswire

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.

10/23/2026, 1:30 PM • GlobeNewswire

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Zymeworks announced a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will receive $55 million upfront and $40 million upon Phase 1b initiation, with potential for up to $718 million in additional milestone payments and tiered royalties on future net sales. Zymeworks will conduct the Phase 1a trial while Roche funds it and handles subsequent development and commercialization.

10/23/2026, 6:00 AM • GlobeNewswire

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

10/22/2026, 1:00 PM • GlobeNewswire

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Roche reported strong Q3 2026 performance with sales growth of +7% at constant exchange rates and +8% in CHF. The Pharmaceuticals Division grew +7% at CER driven by key medicines including Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division grew +4% at CER. The company confirmed its full-year 2026 outlook expecting mid single-digit sales growth and high single-digit core earnings per share growth at CER.

10/22/2026, 1:00 AM • GlobeNewswire